Familial hyperaldosteronism type III a novel case and review of literature.


Journal

Reviews in endocrine & metabolic disorders
ISSN: 1573-2606
Titre abrégé: Rev Endocr Metab Disord
Pays: Germany
ID NLM: 100940588

Informations de publication

Date de publication:
03 2019
Historique:
pubmed: 21 12 2018
medline: 14 4 2020
entrez: 21 12 2018
Statut: ppublish

Résumé

Less than 15% of hypertension cases in children are secondary to a primary hyperaldosteronism. This is idiopathic in 60% of the cases, secondary to a unilateral adenoma in 30% and 10% remaining by primary adrenal hyperplasia, familial hyperaldosteronism, ectopic aldosterone production or adrenocortical carcinoma.To date, four types of familial hyperaldosteronism (FH I to FH IV) have been reported. FH III is caused by germline mutations in KCNJ5, encoding the potassium channel Kir3.4. The mutations cause the channel to lose its selectivity for potassium, allowing large quantities of sodium to enter the cell. As a consequence, the membrane depolarizes, voltage-gated calcium channels open, calcium enters the cell, initiating the cascade that leads to aldosterone synthesis. Somatic mutations in KCNJ5 has also been described in aldosterone-producing adenomas. The most frequent presentation of FH III is with severe hyperaldosteronism symptoms and resistance to pharmacological therapy which leads to bilateral adrenalectomy. We will review current literature and describe a child with FH III due to a novel de novo deletion in KCNJ5 with wild phenotype as a sign of clinical variability of this disease.

Identifiants

pubmed: 30569443
doi: 10.1007/s11154-018-9481-0
pii: 10.1007/s11154-018-9481-0
doi:

Substances chimiques

G Protein-Coupled Inwardly-Rectifying Potassium Channels 0
KCNJ5 protein, human 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

27-36

Références

High Blood Press Cardiovasc Prev. 2016 Sep;23(3):203-8
pubmed: 27136934
Ann Endocrinol (Paris). 2016 Jul;77(3):192-201
pubmed: 27177498
Clin Endocrinol (Oxf). 2015 Dec;83(6):779-89
pubmed: 26252618
J Clin Endocrinol Metab. 2013 Nov;98(11):E1861-5
pubmed: 24037882
Hypertension. 2015 May;65(5):1096-102
pubmed: 25776074
Tohoku J Exp Med. 2016;240(3):183-190
pubmed: 27853054
Trends Endocrinol Metab. 2013 Sep;24(9):421-30
pubmed: 23796656
Clin Exp Pharmacol Physiol. 1991 May;18(5):283-6
pubmed: 2065471
J Hypertens. 2008 Aug;26(8):1577-82
pubmed: 18622235
J Hum Hypertens. 2017 Dec;31(12):776-781
pubmed: 28447626
Science. 2011 Feb 11;331(6018):768-72
pubmed: 21311022
Horm Res Paediatr. 2014;82(2):138-42
pubmed: 24819081
Ann Endocrinol (Paris). 2016 Jul;77(3):202-7
pubmed: 27318644
J Clin Endocrinol Metab. 2016 Nov;101(11):4290-4297
pubmed: 27403928
J Clin Endocrinol Metab. 2014 Sep;99(9):E1765-73
pubmed: 25057880
Elife. 2015 Apr 24;4:e06315
pubmed: 25907736
Hypertension. 2015 Mar;65(3):622-8
pubmed: 25624344
Hypertension. 2011 Nov;58(5):797-803
pubmed: 21876069
Nature. 1992 Jan 16;355(6357):262-5
pubmed: 1731223
J Clin Endocrinol Metab. 2016 May;101(5):1889-916
pubmed: 26934393
J Clin Endocrinol Metab. 2008 Sep;93(9):3266-81
pubmed: 18552288
Trends Endocrinol Metab. 2015 Apr;26(4):201-11
pubmed: 25707577
Ann Endocrinol (Paris). 2016 Jul;77(3):187-91
pubmed: 27087531
J Clin Endocrinol Metab. 2012 Mar;97(3):881-9
pubmed: 22238407
Ann Endocrinol (Paris). 2016 Jul;77(3):226-34
pubmed: 27315759
Mol Cell Endocrinol. 2017 Jan 5;439:74-80
pubmed: 27793677
Ann Endocrinol (Paris). 2016 Jul;77(3):179-86
pubmed: 27315757
J Mol Endocrinol. 2017 Jul;59(1):R47-R63
pubmed: 28400483
Trends Endocrinol Metab. 2013 Jan;24(1):21-30
pubmed: 23040074
J Clin Endocrinol Metab. 2015 Jan;100(1):E114-8
pubmed: 25322277
Hypertension. 2014 Jan;63(1):151-60
pubmed: 24218436
Hypertension. 2010 Sep;56(3):391-6
pubmed: 20696993
Ann Endocrinol (Paris). 2016 Jul;77(3):214-9
pubmed: 27315758
J Clin Endocrinol Metab. 2008 Aug;93(8):3117-23
pubmed: 18505761
Semin Nephrol. 2014 May;34(3):285-306
pubmed: 25016400
Ann Endocrinol (Paris). 2016 Jul;77(3):208-13
pubmed: 27036860
Trends Endocrinol Metab. 2009 Nov;20(9):444-51
pubmed: 19800255
Eur J Endocrinol. 2016 Aug;175(2):K1-6
pubmed: 27165862
Hypertension. 2014 Aug;64(2):354-61
pubmed: 24866132
Eur J Endocrinol. 2018 Mar;178(3):R101-R111
pubmed: 29348113
Ann Endocrinol (Paris). 2016 Jul;77(3):220-5
pubmed: 27297451
World J Hypertens. 2015;5(2):14-27
pubmed: 26413481

Auteurs

Natividad Pons Fernández (N)

Department of Pediatrics, Hospital Lluís Alcanyís de Xàtiva, Ctra. Xàtiva a Silla km 2, 46800, Xàtiva, Valencia, Spain. natividadpons@hotmail.com.

Francisca Moreno (F)

Hospital Universitario y Politécnico la Fe de Valencia, Valencia, Spain.

Julia Morata (J)

Department of Pediatrics, Hospital Lluís Alcanyís de Xàtiva, Ctra. Xàtiva a Silla km 2, 46800, Xàtiva, Valencia, Spain.

Ana Moriano (A)

Department of Pediatrics, Hospital Lluís Alcanyís de Xàtiva, Ctra. Xàtiva a Silla km 2, 46800, Xàtiva, Valencia, Spain.

Sara León (S)

Hospital Universitario y Politécnico la Fe de Valencia, Valencia, Spain.

Carmen De Mingo (C)

Hospital Universitario y Politécnico la Fe de Valencia, Valencia, Spain.

Ángel Zuñiga (Á)

Hospital Universitario y Politécnico la Fe de Valencia, Valencia, Spain.

Fernando Calvo (F)

Department of Pediatrics, Hospital Lluís Alcanyís de Xàtiva, Ctra. Xàtiva a Silla km 2, 46800, Xàtiva, Valencia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH